var data={"title":"Pityriasis rubra pilaris","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pityriasis rubra pilaris</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/contributors\" class=\"contributor contributor_credentials\">Andreas Katsambas, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/contributors\" class=\"contributor contributor_credentials\">Clio Dessinioti, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/contributors\" class=\"contributor contributor_credentials\">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H6824927\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pityriasis rubra pilaris (PRP) is a rare papulosquamous inflammatory dermatosis of unknown origin and considerable clinical heterogeneity (<a href=\"image.htm?imageKey=DERM%2F87505\" class=\"graphic graphic_table graphicRef87505 \">table 1</a>). The cardinal clinical features of PRP are hyperkeratotic follicular papules, orange-red scaling plaques, and palmoplantar hyperkeratosis (<a href=\"image.htm?imageKey=DERM%2F86471%7EDERM%2F86473%7EDERM%2F86472%7EDERM%2F86475%7EDERM%2F86474%7EDERM%2F86476\" class=\"graphic graphic_picture graphicRef86471 graphicRef86473 graphicRef86472 graphicRef86475 graphicRef86474 graphicRef86476 \">picture 1A-F</a>). Well-demarcated areas of spared skin (also known as &quot;islands of sparing&quot;) are a frequent finding in patients with generalized involvement. Erythroderma may occur as a complication of PRP.</p><p>The treatment of PRP can be challenging. Systemic retinoids and <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> are the most commonly employed therapies, and limited data suggest that biologic TNF-alpha inhibitors may be effective. Multiple other therapies have also been utilized for PRP.</p><p>The pathogenesis, diagnosis, and treatment of PRP will be reviewed here.</p><p class=\"headingAnchor\" id=\"H187071461\"><span class=\"h1\">HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A disorder with features consistent with pityriasis rubra pilaris (PRP) was first reported in 1828 as a variant of psoriasis, and in 1856, &quot;pityriasis pilaris&quot; was identified as an independent disease [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/1\" class=\"abstract_t\">1</a>]. The term &quot;pityriasis rubra pilaris&quot; was coined in 1889, and remains the accepted terminology for this disease [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H6824934\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence and prevalence of pityriasis rubra pilaris (PRP) is not precisely known. The disease has been estimated to account for 1 in 5000 new patients who present with skin disease in Great Britain [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. PRP occurs in individuals of all racial backgrounds and appears to affect both genders equally [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>Both adults and children may develop PRP. The disorder has a bimodal age distribution with peaks during the first and fifth decades of life [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H6824941\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathways that lead to the development of pityriasis rubra pilaris (PRP) are unclear. The detection of upregulated expression of TNF-alpha in lesional skin from two patients with PRP and the observation that TNF-alpha inhibitors improve PRP raise the question of whether TNF-alpha plays a significant pathogenic role [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/4\" class=\"abstract_t\">4</a>]. A role for the interleukin (IL)-23-Th17 axis has also been proposed; in a patient treated with <a href=\"topic.htm?path=ustekinumab-drug-information\" class=\"drug drug_general\">ustekinumab</a> (a human monoclonal antibody that targets IL-12 and IL-23), clinical and histologic improvement correlated with the level of expression of Th17 cytokines [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/5\" class=\"abstract_t\">5</a>]. Further study is necessary to determine the pathogenic mechanisms of PRP.</p><p>In addition, abnormalities in <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a> metabolism, an aberrant response to infection, and genetic predisposition have been proposed as factors that may contribute to PRP:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Abnormal </strong><a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a><strong> metabolism </strong>&ndash; The recognition of similarities between the follicular hyperkeratosis of PRP and the cutaneous manifestations of vitamin A deficiency (phrynoderma) led to speculation that vitamin A is involved in the pathogenesis of PRP. After early theories of vitamin A deficiency as a cause of the disease were not substantiated, investigations to determine whether other vitamin A-related factors contribute to PRP were performed. Although a study of 11 adults and children with PRP found that PRP was associated with decreased levels of retinol binding protein (a specific carrier of vitamin A) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/6\" class=\"abstract_t\">6</a>], a subsequent study of 3 patients failed to confirm this finding [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/7\" class=\"abstract_t\">7</a>]. Thus, a role for aberrant vitamin A metabolism in PRP remains uncertain. (See <a href=\"topic.htm?path=overview-of-vitamin-a#H8\" class=\"medical medical_review\">&quot;Overview of vitamin A&quot;, section on 'Deficiency'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infection </strong>&ndash;<strong> </strong>The consideration of infection as a contributor to PRP is based upon case reports documenting the development of PRP following streptococcal and viral infections [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8,9\" class=\"abstract_t\">8,9</a>]. In particular, the coexistence of human immunodeficiency virus (HIV) infection and PRP has been documented in several case reports, and HIV-associated PRP has improved following the initiation of antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"#H427351863\" class=\"local\">'Type VI (HIV-associated)'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Genetics </strong>&ndash;<strong> </strong>Genetic factors play a role in at least some cases of PRP. Although most patients have acquired disease, familial forms of PRP have been described, including cases that appear to result from autosomal dominant transmission with partial penetrance [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/11-13\" class=\"abstract_t\">11-13</a>]. Autosomal dominant PRP has been linked to gain-of-function mutations in the <em>CARD14</em> gene encoding the caspase recruitment domain family, member 14 protein, which is an activator of NF-kappaB [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/11\" class=\"abstract_t\">11</a>]. Furthermore, <em>CARD14 </em>mutations have been detected in a limited number of patients (12.5 percent) with sporadic PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/14\" class=\"abstract_t\">14</a>]. Type V PRP was the clinical variant most strongly associated with mutations in <em>CARD14</em> in a study of 22 patients with PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/15\" class=\"abstract_t\">15</a>]. </p><p/><p>Other factors that have been associated with the development of PRP or exacerbations of PRP include trauma and ultraviolet light [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8,16-19\" class=\"abstract_t\">8,16-19</a>]. In one series of 30 children with PRP, the Koebner phenomenon or trauma preceded the onset of PRP in three children (10 percent) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8\" class=\"abstract_t\">8</a>]. Ultraviolet light exposure from the sun or artificial sources infrequently has been reported as an exacerbating factor for PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/16-18\" class=\"abstract_t\">16-18</a>]. </p><p>Drugs typically are not considered inciting factors for PRP. However, <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a> therapy preceded a PRP-like eruption in one patient with metastatic germ cell cancer [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H6824948\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pityriasis rubra pilaris (PRP) consists of a spectrum of six clinical subtypes. The subtypes of PRP are defined by age of onset, lesion morphology and distribution, disease course, and an association with HIV infection (<a href=\"image.htm?imageKey=DERM%2F87505\" class=\"graphic graphic_table graphicRef87505 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3,21,22\" class=\"abstract_t\">3,21,22</a>]. Type I PRP is the most common form of PRP; type III and type IV are the most common presentations in children [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8,16\" class=\"abstract_t\">8,16</a>].</p><p>Shared features that are present with variable frequency in the subtypes of PRP include follicular hyperkeratosis, orange-red plaques with fine overlying scale, and palmoplantar hyperkeratosis. When large areas of skin are involved, islands of unaffected skin (also known as &quot;islands of sparing&quot;) are often evident. Pruritus is common and palmoplantar hyperkeratosis may result in the development of painful fissures.</p><p>The orange-red color of skin lesions classically described in PRP may not be clearly evident in individuals with dark skin. The orange-red color may be less prominent than in fairer-skinned individuals, and hyperpigmentation or hypopigmentation may be present. </p><p>The clinical subtypes of PRP are reviewed below.</p><p class=\"headingAnchor\" id=\"H427351550\"><span class=\"h2\">Type I (classic adult)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type I PRP, an adult-onset form, is the most common subtype of PRP. This subtype is estimated to account for 55 percent of cases [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. Patients with type I PRP typically present with a cutaneous eruption that progresses in a cephalocaudal manner, beginning with the face and spreading to the trunk, arms, and legs over the course of a few weeks to a few months [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. Hyperkeratotic red to orange follicular papules and plaques accompanied by islands of sparing, and orange-hued hyperkeratosis on the palms and soles are characteristic findings (<a href=\"image.htm?imageKey=DERM%2F86471%7EDERM%2F86473%7EDERM%2F86472%7EDERM%2F86475%7EDERM%2F86474%7EDERM%2F86476\" class=\"graphic graphic_picture graphicRef86471 graphicRef86473 graphicRef86472 graphicRef86475 graphicRef86474 graphicRef86476 \">picture 1A-F</a>). Scaling is fine and powdery (pityriasiform).</p><p>Erythroderma (generalized redness involving more than 90 percent of the body surface area) accompanied by ectropion may develop in PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. However, due to a paucity of data on this phenomenon, the frequency with which this occurs in type I PRP is unclear. </p><p>Approximately 25 percent of the patients we follow at the First Department of Dermatology of the University of Athens for PRP have a history of erythroderma requiring hospitalization. However, our experience likely overestimates the frequency of erythroderma in PRP since patients referred to our hospital-based clinic may be more likely to have severe PRP than patients seen in the general outpatient setting. </p><p>In addition to the skin findings, other abnormalities may occur. Patients may develop rough, thickened nail plates with distal crumbling, yellow-brown discoloration of the nail plate, and the accumulation of subungual debris [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. Moreover, prolonged facial involvement may lead to ectropion [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>], and lymphadenopathy may develop in the setting of extensive skin involvement [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. Associated arthropathy (usually seronegative arthritis) also has been reported [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/24-27\" class=\"abstract_t\">24-27</a>].</p><p>Although the clinical manifestations of type I PRP can be severe, type I PRP generally has a favorable long-term prognosis. Approximately 80 percent of patients achieve spontaneous remission within three years [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H427351778\"><span class=\"h2\">Type II (atypical adult)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type II PRP occurs in adults, but lacks the cephalocaudal progression seen in type I PRP. The most prominent features in this variant are an ichthyosiform dermatitis that tends to be most prominent on the lower extremities. The palmoplantar hyperkeratosis tends to be coarse with lamellated scale. Sparse scalp hair is occasionally present. </p><p>The prognosis of type II PRP is less favorable than type I PRP. The disease may have a protracted course of more than 20 years. Fewer than 20 percent of patients achieve clinical resolution within three years [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H427351705\"><span class=\"h2\">Type III (classic juvenile)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations of type I and type III PRP are similar, with the age of onset as the distinguishing factor (<a href=\"image.htm?imageKey=DERM%2F87152%7EDERM%2F87153%7EDERM%2F87154\" class=\"graphic graphic_picture graphicRef87152 graphicRef87153 graphicRef87154 \">picture 2A-C</a>). While type I PRP develops in adulthood, type III PRP typically begins around 5 to 10 years of age [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. Type III PRP is less common than type I PRP, accounting for approximately 10 percent of cases [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>Similar to type I PRP, erythroderma can occur in type III PRP. One retrospective series that included 17 children with type III PRP found that 4 of these children (24 percent) had erythroderma [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8\" class=\"abstract_t\">8</a>].</p><p>The prognosis of type III PRP is excellent. Most patients experience disease resolution after one year [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. Rarely, the disease is persistent [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H427351790\"><span class=\"h2\">Type IV (circumscribed juvenile)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This form of PRP accounts for approximately 25 percent of cases of PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. Type IV PRP primarily occurs in prepubertal children [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. Young adults may also be affected. </p><p>Patients present with sharply demarcated areas of erythema and follicular hyperkeratosis on the elbows and knees. Palmoplantar hyperkeratosis may be present [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The disease may demonstrate a relapsing and remitting course. Approximately one-third of patients achieve disease remission within three years [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. Progression to widespread, classic PRP usually does not occur.</p><p class=\"headingAnchor\" id=\"H427351843\"><span class=\"h2\">Type V (atypical juvenile)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type V PRP is relatively uncommon, representing around 5 percent of cases [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. The majority of familial cases of PRP fall into this category. The disease manifestations begin in the first few years of life and include follicular hyperkeratosis and generalized ichthyosiform dermatitis [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/16\" class=\"abstract_t\">16</a>]. Erythema is usually present, but not prominent [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>]. Occasional patients exhibit scleroderma-like changes on the palms and soles. The disease course is usually chronic.</p><p class=\"headingAnchor\" id=\"H427351863\"><span class=\"h2\">Type VI (HIV-associated)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PRP may occur in the setting of HIV-infection, in some cases representing the initial manifestations of disease [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/10,22,30\" class=\"abstract_t\">10,22,30</a>]. Patients develop widely-distributed erythematous follicular papules with prominent keratotic spicules and inflammatory plaques. The presence of nail, palmar, and plantar changes is variable. Erythroderma is a frequent complication [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"abstract_t\">23</a>]. </p><p>HIV-associated PRP may occur in concert with other disorders characterized by follicular occlusion, including acne conglobata, hidradenitis suppurativa, and lichen spinulosus [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/10,22,31,32\" class=\"abstract_t\">10,22,31,32</a>]. </p><p class=\"headingAnchor\" id=\"H567847\"><span class=\"h2\">Mucosal involvement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral involvement in PRP is rare and may appear as white papules or plaques on the palate, buccal mucosa, <span class=\"nowrap\">and/or</span> tongue [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/33\" class=\"abstract_t\">33</a>]. Discomfort may be present. </p><p>Ocular complications reported in the setting of PRP include cicatricial ectropion and peripheral ulcerative keratitis [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/34,35\" class=\"abstract_t\">34,35</a>]. The development of bilateral herpes simplex virus keratitis was reported in one patient with PRP during treatment with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> and <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H61283694\"><span class=\"h1\">ASSOCIATED DISORDERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to HIV infection, several immunodeficient states and autoimmune disorders have been reported in association with pityriasis rubra pilaris (PRP) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/37\" class=\"abstract_t\">37</a>], suggesting that immunologic dysfunction may be a contributing factor. In addition, several case reports document the occurrence of PRP in the setting of internal malignancy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/38-44\" class=\"abstract_t\">38-44</a>]. The relationship between PRP and these types of disorders remains uncertain. With the exception of testing for HIV infection, we do not routinely screen patients for associated diseases in the absence of signs of symptoms suggestive of an underlying disease. </p><p class=\"headingAnchor\" id=\"H6824990\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of pityriasis rubra pilaris (PRP) is based on the recognition of consistent clinical and histopathologic features. There are no specific serologic markers for PRP. </p><p class=\"headingAnchor\" id=\"H427352175\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A 4 mm punch biopsy is typically utilized to obtain a specimen for histologic examination. Findings classically seen include [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/45\" class=\"abstract_t\">45</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Orthokeratosis with spotty parakeratosis (alternating orthokeratosis and parakeratosis in vertical and horizontal directions; parakeratosis surrounding follicular ostia)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidermal acanthosis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intact granular layer </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild perivascular lymphohistiocytic infiltrate in the dermis</p><p/><p>Occasional additional findings include epidermal spongiosis and focal acantholytic dyskeratosis.</p><p class=\"headingAnchor\" id=\"H427352191\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of pityriasis rubra pilaris (PRP) varies according to the clinical subtype. The most common disorder in the differential for type I and type III PRP is psoriasis vulgaris.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Psoriasis vulgaris </strong>&ndash; Psoriasis vulgaris can be difficult to distinguish from PRP due to the fact that both conditions may present with localized or widespread erythematous, scaly plaques. PRP is characterized by red to orange follicular papules and plaques and orange palmoplantar keratoderma. Psoriasis is characterized by silvery, coarse scales that are loosely adhered to sharply demarcated red (erythematous) plaques. These scales contrast with the finer scales that develop in PRP. Also, typical nail changes (eg, oil spots, pitting) of psoriasis are useful in distinguishing between psoriasis and PRP (<a href=\"image.htm?imageKey=DERM%2F70962%7EDERM%2F66374\" class=\"graphic graphic_picture graphicRef70962 graphicRef66374 \">picture 3A-B</a>). </p><p/><p class=\"bulletIndent1\">Histologic examination also is of value. Unlike PRP, the granular layer is absent in psoriasis. In addition, collections of polymorphonuclear leukocytes (Munro microabscesses) are often found in the epidermis in psoriasis. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of psoriasis&quot;</a>.)</p><p/><p>The distribution of early PRP on the face and photo-exposed body areas may stimulate consideration of a photo-aggravated disorder. (See <a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment&quot;</a>.) </p><p>In patients who present with erythroderma, the possibility of other diseases that cause erythroderma must be considered. A medical history, careful physical examination for associated clinical features, and skin biopsy can help to determine the underlying cause. Examples of diseases that may present with erythroderma include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Psoriasis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atopic dermatitis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug eruptions</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous T-cell lymphoma</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Congenital ichthyoses</p><p/><p>In the case of inconclusive histology, immunohistochemistry and T cell receptor gene rearrangement studies (by PCR) may be necessary to rule out cutaneous T-cell lymphoma.</p><p>Type II and V PRP may present with ichthyosiform changes, and congenital or acquired ichthyoses should be considered in the differential diagnosis of these subtypes. (See <a href=\"topic.htm?path=the-genodermatoses#H3\" class=\"medical medical_review\">&quot;The genodermatoses&quot;, section on 'Ichthyoses'</a>.)</p><p>For patients with type IV PRP, which is characterized by localized plaques with follicular hyperkeratosis, other disorders with follicular hyperkeratosis in limited areas, such as lichen spinulosus and keratosis pilaris, should be considered. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lichen spinulosus </strong>&ndash; Lichen spinulosus is an uncommon disorder that most commonly presents in children and adolescents as circumscribed plaques with follicular papules that bear keratotic spines (<a href=\"image.htm?imageKey=DERM%2F87590\" class=\"graphic graphic_picture graphicRef87590 \">picture 4</a>). The neck, abdomen, and upper and lower extremities are sites of disease predilection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Keratosis pilaris (follicular hyperkeratosis) </strong>&ndash; Keratosis pilaris is a common skin condition often associated with atopy. Patients present with spiny follicular papules on the upper arms, thighs, and buttocks (<a href=\"image.htm?imageKey=DERM%2F68488%7EDERM%2F60786\" class=\"graphic graphic_picture graphicRef68488 graphicRef60786 \">picture 5A-B</a>). </p><p/><p class=\"headingAnchor\" id=\"H6824997\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of pityriasis rubra pilaris (PRP) is largely based upon anecdotal reports of clinical experience. Because no controlled trials have been performed, there is uncertainty regarding the true efficacy of individual treatments. No treatments have been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for use in PRP.</p><p class=\"headingAnchor\" id=\"H427352246\"><span class=\"h2\">Approach to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of PRP involves the combined use of systemic and topical therapies. Topical therapies help with the management of associated symptoms and may be sufficient as monotherapy for patients with limited disease. However, most patients require systemic therapy to attain control of PRP.</p><p>Oral retinoids (synthetic <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a> derivatives) are the preferred first-line systemic treatments for children and adults with PRP. Case reports and case series support the efficacy of systemic retinoids in PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8,27,35,46-52\" class=\"abstract_t\">8,27,35,46-52</a>]. (See <a href=\"#H427352254\" class=\"local\">'Systemic retinoids'</a> below.)</p><p>Multiple other treatments are utilized for PRP. <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> has appeared effective in case reports and case series, and is an alternative treatment option for patients who are not good candidates for systemic retinoids or who fail to respond to systemic retinoid therapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/52\" class=\"abstract_t\">52</a>]. Additional agents such as biologic TNF-alpha inhibitors, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, and phototherapy may be useful for patients who fail to respond adequately to retinoid or methotrexate therapy.</p><p>Data on the treatment of HIV-associated PRP are limited. Improvement after treatment with <a href=\"topic.htm?path=zidovudine-drug-information\" class=\"drug drug_general\">zidovudine</a> alone, systemic retinoids plus zidovudine, or triple antiviral therapy has been reported [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H562911\"><span class=\"h2\">Topical therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical treatments used for PRP include medium to high potency topical corticosteroids (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8,27,53\" class=\"abstract_t\">8,27,53</a>], keratolytics, tar, calcipotriene (<a href=\"topic.htm?path=calcipotriol-calcipotriene-drug-information\" class=\"drug drug_general\">calcipotriol</a>) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/54\" class=\"abstract_t\">54</a>], <a href=\"topic.htm?path=topical-tretinoin-topical-all-trans-retinoic-acid-drug-information\" class=\"drug drug_general\">topical tretinoin</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/55\" class=\"abstract_t\">55</a>], and <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">tazarotene</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/56\" class=\"abstract_t\">56</a>]. Topical treatments are usually combined with a systemic therapy for PRP types affecting a large body surface area. For patients with limited skin involvement, local therapy may be beneficial as monotherapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Topical keratolytics (such as 10% urea or 5% salicylic acid) may be useful for managing hyperkeratosis and palmoplantar keratoderma. In addition, the application of emollients and the administration of systemic antihistamines for pruritus may help to reduce associated symptoms. In our experience, daily application of topical emollients is beneficial for improving skin texture and the degree of scaling, erythema, and induration of the lesions. </p><p>Data on the use of topical agents in PRP are derived mainly from case reports. As a result, there are no high-quality evidence-based data regarding efficacy and safety of topical treatment. Treatment with topical corticosteroids should in general be limited to small body areas and for a short period of time due to the risk of side effects, such as skin atrophy, telangiectasias, and systemic absorption. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a>.)</p><p class=\"headingAnchor\" id=\"H427352231\"><span class=\"h2\">Systemic therapy</span></p><p class=\"headingAnchor\" id=\"H427352357\"><span class=\"h3\">First-line systemic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic retinoids are used as first-line systemic therapy for adults and children with PRP based upon data from case reports and clinical experience. The response to treatment is variable. </p><p class=\"headingAnchor\" id=\"H427352254\"><span class=\"h4\">Systemic retinoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The preferred use of retinoids for patients with PRP is based upon the beneficial effects of retinoids observed in case reports and case series [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8,27,35,46-52\" class=\"abstract_t\">8,27,35,46-52</a>]. The most common retinoids used for the treatment of PRP are <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> and <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>. Case reports and a small retrospective study suggest that a newer retinoid, <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">alitretinoin</a>, may also be effective for PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/57-60\" class=\"abstract_t\">57-60</a>].</p><p>The response to retinoid therapy is usually evident within three to six months, although longer courses of treatment are necessary in some patients [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/46\" class=\"abstract_t\">46</a>]. Examples of reports documenting treatment efficacy include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective study of 40 patients with PRP included 12 patients (nine males and three postmenopausal females) with type I PRP treated with oral <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/27\" class=\"abstract_t\">27</a>]. Eight patients received acitretin alone at a dose of 25 to 50 mg per day, two patients were treated with acitretin combined with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, and two patients were treated with acitretin (50 mg per day) combined with <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> (300 to 400 mg twice daily). Partial or marked clinical responses were documented for all 12 patients. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an early prospective study in which 45 patients with PRP were treated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (mean dose 2 <span class=\"nowrap\">mg/kg</span> per day), 28 of 45 patients (62 percent) were noted by clinician evaluators to have marked improvement within four weeks, and all 34 patients who returned for clinician evaluation after 12 to 16 weeks of treatment had marked improvement [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among 15 patients treated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (primarily 40 mg twice daily) in a retrospective study of adolescents and adults with PRP, 10 patients (67 percent) achieved complete clearance within an average of 25 weeks (range 16 to 44 weeks), 2 achieved partial clearing after 16 and 24 weeks, and 3 patients failed to respond after 20 to 24 weeks [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/46\" class=\"abstract_t\">46</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective review of 18 patients with PRP, among 15 patients who were treated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (0.5 to 2.2 <span class=\"nowrap\">mg/kg</span> per day), 7 (47 percent) achieved complete clearance (most within seven months), 3 (20 percent) achieved partial clearance, and 5 (33 percent) failed to respond to therapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/48\" class=\"abstract_t\">48</a>]. The average dose of isotretinoin for patients who achieved complete clearance was 1 <span class=\"nowrap\">mg/kg</span> per day. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of 30 adolescents and children with PRP who were under the age of 20 years, five of six patients with type III PRP who were treated with <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (0.75 to 1.5 <span class=\"nowrap\">mg/kg</span> per day) achieved 90 to 100 percent disease clearance within six months [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8\" class=\"abstract_t\">8</a>]. In contrast, only one of six patients treated with <a href=\"topic.htm?path=vitamin-a-drug-information\" class=\"drug drug_general\">vitamin A</a> (&gt;100,000 U per day) had excellent improvement.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study, four of five adults given <a href=\"topic.htm?path=alitretinoin-drug-information\" class=\"drug drug_general\">alitretinoin</a> (30 mg per day) for type I PRP had reductions in disease severity within four to eight weeks [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/59\" class=\"abstract_t\">59</a>]. The fifth patient discontinued alitretinoin because of disease progression during the first three weeks. Among the responders, alitretinoin was well tolerated with the exception of one patient who experienced up to threefold elevations of creatinine kinase and hepatic transaminases compared with normal serum levels after 22 weeks of treatment.</p><p/><p>In clinical practice, typical retinoid doses used for adults with PRP are <strong>1 <span class=\"nowrap\">mg/kg</span> per day of </strong><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> and <strong>0.5 <span class=\"nowrap\">mg/kg</span> per day of </strong><a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>. The appropriate dose regimen for systemic retinoids for PRP is less established in children. </p><p>Adverse effects of retinoid therapy include dry skin and mucous membranes, hyperlipidemia, transaminase elevations, and visual or bone changes [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/61\" class=\"abstract_t\">61</a>]. Premature epiphyseal closure is a rare side effect of retinoid therapy that may occur in children, particularly in children treated with high doses [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/62\" class=\"abstract_t\">62</a>]. Retinoids are teratogenic and must not be used by women who are pregnant or who are at risk of becoming pregnant but decline strict use of reliable contraceptives (two complementary forms of contraception including a barrier method) to prevent pregnancy. (See <a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris#H7\" class=\"medical medical_review\">&quot;Oral isotretinoin therapy for acne vulgaris&quot;, section on 'Isotretinoin safety'</a>.)</p><p>Because alcohol ingestion may stimulate the in vivo conversion of <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> to etretinate (a retinoid with an exceptionally long elimination half-life), pregnancy must be avoided during and for three years after treatment with acitretin [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/63\" class=\"abstract_t\">63</a>]. Thus, treatment with acitretin is not recommended in women of childbearing potential [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/64\" class=\"abstract_t\">64</a>]. Pregnancy must be avoided during and for six weeks after <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> therapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/65\" class=\"abstract_t\">65</a>]. Participation in the iPLEDGE program (<a href=\"http://www.ipledgeprogram.com/&amp;token=P8TWCZAjeR8PUAmmngoTNM42X/3zlLk7kCgUxF48u8lvPdS4hlqHClPodeqVKM3g&amp;TOPIC_ID=15283\" target=\"_blank\" class=\"external\">www.ipledgeprogram.com</a>), which is required for prescribing isotretinoin in the United States, requires that females treated with isotretinoin continue use of two forms of contraception until one month after the last isotretinoin dose.</p><p class=\"headingAnchor\" id=\"H427352372\"><span class=\"h3\">Second-line systemic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> (5 to 25 mg per week) can be used as next-line treatment for patients who fail systemic retinoids or who have comorbidities or other characteristics that prohibit the use of systemic retinoid therapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/51,61,66\" class=\"abstract_t\">51,61,66</a>].</p><p class=\"headingAnchor\" id=\"H427352268\"><span class=\"h4\">Methotrexate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Small retrospective studies have supported the use of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> in PRP. Although one author's 1980 review of personal clinical experience and published cases identified a response to methotrexate in only 17 of 44 patients (39 percent) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"abstract_t\">3</a>], other studies have found more favorable results. Among eight patients with type I PRP treated with 10 to 25 mg per week of methotrexate in a retrospective study, all achieved favorable responses within several months [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/46\" class=\"abstract_t\">46</a>]. The average duration of treatment was six months (range 1 to 12 months). In another retrospective study, all five adults with PRP improved with methotrexate, including two who had previously failed to respond to retinoids [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/51\" class=\"abstract_t\">51</a>]. The average duration of treatment was 12 months.</p><p><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> has also been used in combination with systemic retinoids in difficult cases. In a retrospective study that included six patients who were given combination therapy with a retinoid and methotrexate (5 to 30 mg per week) because of severe disease and five patients for whom methotrexate was added to a systemic retinoid due to a failure to respond to the retinoid alone, 8 of 11 patients achieved at least 50 percent improvement, and four patients achieved greater than 95 percent improvement by 16 weeks [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/49\" class=\"abstract_t\">49</a>]. Although treatment appeared to be well tolerated, increased risk for hepatoxicity is a concern with combination therapy. </p><p>Gastrointestinal distress is a common adverse effect of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>. Additional serious adverse effects include pancytopenia, hepatotoxicity, and pneumonitis. Methotrexate is teratogenic and should not be given in pregnancy. (See <a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate\" class=\"medical medical_review\">&quot;Major side effects of low-dose methotrexate&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H427352387\"><span class=\"h3\">Additional therapies</span></p><p class=\"headingAnchor\" id=\"H427352330\"><span class=\"h4\">Biologic agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Biologic therapies have been used as treatments for PRP (adult- or juvenile-onset) in case series and case reports. </p><p>In the majority of cases, biologic TNF-alpha inhibitors (<a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/27,67-70\" class=\"abstract_t\">27,67-70</a>], <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/7-13,16-51,53-58,61,63,64,66,67,71-76\" class=\"abstract_t\">7-13,16-51,53-58,61,63,64,66,67,71-76</a>], or <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/4,76-79\" class=\"abstract_t\">4,76-79</a>]) were used after failure of preceding treatments, such as <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>. In addition, most patients received short-term treatment, given in combination with acitretin or <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>. In our practice, a 27-year-old woman with a 14-year history of type III PRP that had been refractory to systemic retinoids and narrowband UVB phototherapy appeared to benefit from long-term anti-TNF-alpha monotherapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/29\" class=\"abstract_t\">29</a>]. The patient responded to periodic infusions of infliximab (5 <span class=\"nowrap\">mg/kg</span> every seven weeks after induction), achieving 80 percent clearance after 2.5 years. Treatment was well tolerated. </p><p>A systematic review of type I PRP reported 15 patients treated with biologic anti-TNF agents, of whom 12 (80 percent) responded completely to treatment, two responded partially, and one failed to respond. [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/76\" class=\"abstract_t\">76</a>]. Six patients received <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a>, or <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a> as monotherapy and the remainder were simultaneously treated with other agents (primarily <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> or <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>). The mean time for an initial response to treatment among partial or complete responders was five weeks, and among patients who experienced a complete response, a mean of five months was required to reach maximal improvement. </p><p>A retrospective study of 40 patients with PRP included nine patients treated with anti-TNF-alpha agents, offering additional data regarding their efficacy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/27\" class=\"abstract_t\">27</a>]. Partial or marked clinical responses were documented for all nine patients (eight with type I PRP and one with type V PRP) treated with anti-TNF-alpha biologic therapy, with a notable clinical response evident within an average of five to seven weeks. All of these patients had been previously treated with other therapies for PRP and most received the biologic TNF-alpha inhibitor in conjunction with another systemic drug (<a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a>, or <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>) or UVA1 phototherapy. During follow-up, three of these nine patients were able to discontinue treatment and sustain complete clearance. </p><p>In sum, the findings of these studies suggest a beneficial effect of biologic TNF-alpha inhibitors on PRP. However, as 80 percent of type I PRP patients achieve spontaneous remission within three years, the absence of controlled trials makes it difficult to evaluate the efficacy of TNF-alpha inhibitors in type I PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/76\" class=\"abstract_t\">76</a>]. </p><p>Another biologic agent, <a href=\"topic.htm?path=ustekinumab-drug-information\" class=\"drug drug_general\">ustekinumab</a> (a human monoclonal antibody that targets interleukin [IL]-12 and IL-23), has been associated with improvement in type I PRP and familial PRP in case reports [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/5,80-82\" class=\"abstract_t\">5,80-82</a>]. However, data are insufficient to recommend the routine use of ustekinumab for PRP. Some authors have suggested reserving its use for patients who fail to respond with conventional systemic therapies or anti-TNF-alpha biologic agents [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/83\" class=\"abstract_t\">83</a>]. </p><p><a href=\"topic.htm?path=secukinumab-drug-information\" class=\"drug drug_general\">Secukinumab</a>, an anti-IL-17A antibody used for the treatment of psoriasis, was associated with improvement in type I PRP in one patient previously refractory to <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> treatment [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/84\" class=\"abstract_t\">84</a>]. Additional study is necessary to confirm efficacy of secukinumab for PRP. </p><p>Reactivation or exacerbations of infections are potential side effects of biologic TNF-alpha inhibitors, <a href=\"topic.htm?path=ustekinumab-drug-information\" class=\"drug drug_general\">ustekinumab</a>, and <a href=\"topic.htm?path=secukinumab-drug-information\" class=\"drug drug_general\">secukinumab</a>. Thus, pretreatment laboratory investigations for these agents include screening for hepatitis B and hepatitis C, as well as screening for tuberculosis using a purified protein derivative (PPD) skin test or interferon-gamma release assay and a chest radiograph if indicated (see <a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a>). Testing for human immunodeficiency virus infection should also be considered.</p><p>The adverse effects of biologic therapies are reviewed in greater detail separately. (See <a href=\"topic.htm?path=tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects\" class=\"medical medical_review\">&quot;Tumor necrosis factor-alpha inhibitors: An overview of adverse effects&quot;</a> and <a href=\"topic.htm?path=treatment-of-psoriasis-in-adults#H42\" class=\"medical medical_review\">&quot;Treatment of psoriasis in adults&quot;, section on 'Ustekinumab'</a>.)</p><p class=\"headingAnchor\" id=\"H563751\"><span class=\"h4\">Phototherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although a few case reports document photoexacerbation of PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/17,85-87\" class=\"abstract_t\">17,85-87</a>], phototherapy may be useful in some patients. PUVA therapy has yielded variable results in case reports and a small case series [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/86,88,89\" class=\"abstract_t\">86,88,89</a>], and successful treatment with narrowband UVB has been reported in at least two patients [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/90,91\" class=\"abstract_t\">90,91</a>]. In a retrospective study, the Goeckerman treatment regimen, which combines topical tar and UVB phototherapy, was associated with a good response in one of eight children [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8\" class=\"abstract_t\">8</a>]; however, this treatment failed to result in clinically significant improvement in any of 17 patients in a separate retrospective series [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/46\" class=\"abstract_t\">46</a>].</p><p>The combination of retinoids and phototherapy may be effective. <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">Acitretin</a> combined with narrowband UVB [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/92,93\" class=\"abstract_t\">92,93</a>], UVA1 [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/94\" class=\"abstract_t\">94</a>], or PUVA (Re-PUVA) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/35,95,96\" class=\"abstract_t\">35,95,96</a>] has been reported as beneficial in small numbers of patients. </p><p>Due to the possibility of photoexacerbation of PRP, performing phototesting prior to the initiation of treatment is suggested [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23,97\" class=\"abstract_t\">23,97</a>].</p><p class=\"headingAnchor\" id=\"H1140890749\"><span class=\"h4\">Immunosuppressants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunosuppressants, such as <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/98-100\" class=\"abstract_t\">98-100</a>] and <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3,101,102\" class=\"abstract_t\">3,101,102</a>], have been reported to be effective for PRP in case reports. However, cyclosporine (6 <span class=\"nowrap\">mg/kg</span> per day for six to eight weeks) was associated with minimal clinical improvement in a series of three adults with PRP [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/103\" class=\"abstract_t\">103</a>]. The limited data to support the efficacy of these agents and concerns regarding the potential for severe adverse effects limit the use of these agents. (See <a href=\"topic.htm?path=pharmacology-of-cyclosporine-and-tacrolimus\" class=\"medical medical_review\">&quot;Pharmacology of cyclosporine and tacrolimus&quot;</a> and <a href=\"topic.htm?path=pharmacology-and-side-effects-of-azathioprine-when-used-in-rheumatic-diseases#H7\" class=\"medical medical_review\">&quot;Pharmacology and side effects of azathioprine when used in rheumatic diseases&quot;, section on 'Adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H427352338\"><span class=\"h4\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional therapies that have been reported to be effective in individual patients with PRP include fumaric acid esters [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/104\" class=\"abstract_t\">104</a>], penicillin [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/105,106\" class=\"abstract_t\">105,106</a>], extracorporeal photochemotherapy [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/107\" class=\"abstract_t\">107</a>], intravenous immunoglobulin [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/108\" class=\"abstract_t\">108</a>], and <a href=\"topic.htm?path=apremilast-drug-information\" class=\"drug drug_general\">apremilast</a> (an oral phosphodiesterase 4 (PDE 4) inhibitor used for the treatment of plaque psoriasis and psoriatic arthritis) [<a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/109\" class=\"abstract_t\">109</a>].</p><p class=\"headingAnchor\" id=\"H6825039\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prognosis of pityriasis rubra pilaris (PRP) is dependent upon the clinical subtype. (See <a href=\"#H6824948\" class=\"local\">'Clinical manifestations'</a> above.)</p><p>Recurrence of PRP after treatment cessation is unpredictable. Patients may remain in remission or may experience disease recurrence after the discontinuation of systemic therapy. </p><p class=\"headingAnchor\" id=\"H1140890684\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pityriasis rubra pilaris (PRP) is a rare papulosquamous inflammatory dermatosis. The cardinal clinical features of PRP include follicular hyperkeratosis, palmoplantar hyperkeratosis, and orange-red scaling plaques.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PRP is classified into six clinical types (I-VI) according to age at onset, clinical presentation, and expected prognosis (<a href=\"image.htm?imageKey=DERM%2F87505\" class=\"graphic graphic_table graphicRef87505 \">table 1</a>). PRP occurs in both adults and children. (See <a href=\"#H6824934\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Classical PRP is the most common form of PRP. It is divided into adult-onset (type I) and juvenile onset (type III) forms, with similar clinical characteristics (<a href=\"image.htm?imageKey=DERM%2F86471%7EDERM%2F86473%7EDERM%2F86472%7EDERM%2F86475%7EDERM%2F86474%7EDERM%2F86476%7EDERM%2F87152%7EDERM%2F87153%7EDERM%2F87154\" class=\"graphic graphic_picture graphicRef86471 graphicRef86473 graphicRef86472 graphicRef86475 graphicRef86474 graphicRef86476 graphicRef87152 graphicRef87153 graphicRef87154 \">picture 1A-F, 2A-C</a>). Other types are atypical adult (type II) PRP, circumscribed juvenile (type IV), atypical juvenile (type V), and HIV-associated (type VI) PRP.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common clinical subtype of PRP, type I (classic adult) PRP, occurs in adults and is characterized by follicular hyperkeratosis, orange-red inflammatory plaques, and palmoplantar hyperkeratosis. Well-demarcated areas of uninvolved skin (&quot;islands of sparing&quot;) are a common finding. Erythroderma may occur. (See <a href=\"#H6824948\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common forms of PRP in children are type III (classic juvenile) and type IV (circumscribed juvenile). The clinical features of type III PRP are identical to type I PRP. Type IV PRP is a unique form that presents with sharply demarcated erythematous plaques with prominent follicular hyperkeratosis. The elbows and knees are common sites of involvement. (See <a href=\"#H6824948\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PRP occurs in association with HIV infection (type VI PRP). Widespread hyperkeratotic and erythematous follicular papules are typically present. Erythroderma is a frequent complication. (See <a href=\"#H427351863\" class=\"local\">'Type VI (HIV-associated)'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of PRP is made based upon the clinical and pathologic findings. The differential diagnosis includes psoriasis, drug eruptions, cutaneous T cell lymphoma, keratosis pilaris, and ichthyosis. (See <a href=\"#H6824990\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Data are limited on the treatments for PRP. Patients with limited disease (eg, type IV PRP) may be managed with topical therapy. For adults and children with more extensive PRP, we suggest treatment with a systemic retinoid such as <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> or <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> as initial therapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Due to the need to abstain from pregnancy for three years after treatment with acitretin, use of acitretin is not recommended in women of reproductive potential. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate</a> is an alternative treatment option for patients with PRP. Methotrexate is teratogenic and is contraindicated during pregnancy. (See <a href=\"#H6824997\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TNF-alpha inhibitors, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, or <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> may be effective for patients who fail to respond to retinoids and <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>. (See <a href=\"#H427352387\" class=\"local\">'Additional therapies'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/1\" class=\"nounderline abstract_t\">Devergie MGA. Pityriasis pilaris, maladie de peau non decrite par les dermatologists. Gazette Hebdomadaire de medicine et de chirurgie 1856; 3:197.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/2\" class=\"nounderline abstract_t\">Besnier E. Observations pour servir a l&rsquo;histoire Clinique du pityriasis rubra pilaire. Ann Derm Syph Ser 1889; 10:253.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/3\" class=\"nounderline abstract_t\">Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:105.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/4\" class=\"nounderline abstract_t\">Zhang YH, Zhou Y, Ball N, et al. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg 2010; 14:185.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/5\" class=\"nounderline abstract_t\">Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. JAMA Dermatol 2017; 153:304.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/6\" class=\"nounderline abstract_t\">Finzi AF, Altomare G, Bergamaschini L, Tucci A. Pityriasis rubra pilaris and and retinol-binding protein. Br J Dermatol 1981; 104:253.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/7\" class=\"nounderline abstract_t\">Stoll DM, King LE Jr, Chytil F. Serum levels of retinol binding protein in patients with pityriasis rubra pilaris. Br J Dermatol 1983; 108:375.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/8\" class=\"nounderline abstract_t\">Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol 2002; 47:386.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/9\" class=\"nounderline abstract_t\">Kawara S, Miyake M, Oiso N, Kawada A. Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology 2009; 219:350.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/10\" class=\"nounderline abstract_t\">Blasdale C, Turner RJ, Leonard N, et al. Spontaneous clinical improvement in HIV-associated follicular syndrome. Clin Exp Dermatol 2004; 29:480.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/11\" class=\"nounderline abstract_t\">Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012; 91:163.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/12\" class=\"nounderline abstract_t\">Vanderhooft SL, Francis JS, Holbrook KA, et al. Familial pityriasis rubra pilaris. Arch Dermatol 1995; 131:448.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/13\" class=\"nounderline abstract_t\">Vasher M, Smithberger E, Lien MH, Fenske NA. Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept. J Drugs Dermatol 2010; 9:844.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/14\" class=\"nounderline abstract_t\">Li Q, Jin Chung H, Ross N, et al. Analysis of CARD14 Polymorphisms in Pityriasis Rubra Pilaris: Activation of NF-&kappa;B. J Invest Dermatol 2015; 135:1905.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/15\" class=\"nounderline abstract_t\">Takeichi T, Sugiura K, Nomura T, et al. Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations. JAMA Dermatol 2017; 153:66.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/16\" class=\"nounderline abstract_t\">Yang CC, Shih IH, Lin WL, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol 2008; 59:943.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/17\" class=\"nounderline abstract_t\">Evangelou G, Murdoch SR, Palamaras I, Rhodes LE. Photoaggravated pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed 2005; 21:272.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/18\" class=\"nounderline abstract_t\">Iredale HE, Meggitt SJ. Photosensitive pityriasis rubra pilaris. Clin Exp Dermatol 2006; 31:36.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/19\" class=\"nounderline abstract_t\">Davidson CL Jr, Winkelmann RK, Kierland RR. Pityriasis rubra pilaris. A follow-up study of 57 patients. Arch Dermatol 1969; 100:175.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/20\" class=\"nounderline abstract_t\">Paz C, Querfeld C, Shea CR. Sorafenib-induced eruption resembling pityriasis rubra pilaris. J Am Acad Dermatol 2011; 65:452.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/21\" class=\"nounderline abstract_t\">Griffiths WA, Ozluer S. [Pityriasis rubra pilaris]. Ann Dermatol Venereol 2001; 128:931.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/22\" class=\"nounderline abstract_t\">Miralles ES, N&uacute;&ntilde;ez M, De Las Heras ME, et al. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol 1995; 133:990.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/23\" class=\"nounderline abstract_t\">Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010; 11:157.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/24\" class=\"nounderline abstract_t\">Fiallo P, Tagliapietra AG, Santoro G. Arthropathic pityriasis rubra pilaris. Br J Dermatol 1996; 134:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/25\" class=\"nounderline abstract_t\">Conaghan PG, Sommer S, McGonagle D, et al. The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. Arthritis Rheum 1999; 42:1998.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/26\" class=\"nounderline abstract_t\">Lister RK, Perry JD, Cerio R. Pityriasis rubra pilaris and a seronegative polyarthritis. Br J Dermatol 1997; 137:318.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/27\" class=\"nounderline abstract_t\">Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol 2014; 150:92.</a></li><li class=\"breakAll\">Wood GS, Reizner GT. Other papulosquamous disorders. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier, Philadelphia; London 2012. Vol 1, p.157.</li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/29\" class=\"nounderline abstract_t\">Dessinioti C, Vergou T, Moustou E, et al. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol 2011; 21:599.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/30\" class=\"nounderline abstract_t\">De D, Dogra S, Narang T, et al. Pityriasis rubra pilaris in a HIV-positive patient (Type 6 PRP). Skinmed 2008; 7:47.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/31\" class=\"nounderline abstract_t\">Gonz&aacute;lez-L&oacute;pez A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol 1999; 140:931.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/32\" class=\"nounderline abstract_t\">Martin AG, Weaver CC, Cockerell CJ, Berger TG. Pityriasis rubra pilaris in the setting of HIV infection: clinical behaviour and association with explosive cystic acne. Br J Dermatol 1992; 126:617.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/33\" class=\"nounderline abstract_t\">Martinez Calixto LE, Suresh L, Matsumura E, et al. Oral pityriasis rubra pilaris. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101:604.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/34\" class=\"nounderline abstract_t\">Paranjothy B, Shunmugam M, MacKenzie J, Azuara-Blanco A. Peripheral ulcerative keratitis in pityriasis rubra pilaris. Eye (Lond) 2007; 21:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/35\" class=\"nounderline abstract_t\">Gemmeke A, Sch&ouml;nlebe J, Koch A, Wollina U. Pityriasis rubra pilaris--a retrospective single center analysis over eight years. J Dtsch Dermatol Ges 2010; 8:439.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/36\" class=\"nounderline abstract_t\">Kitzmann AS, Goins KM, Syed NA, Wagoner MD. Bilateral herpes simplex keratitis with unilateral secondary bacterial keratitis and corneal perforation in a patient with pityriasis rubra pilaris. Cornea 2008; 27:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/37\" class=\"nounderline abstract_t\">Sehgal VN, Srivastava G. (Juvenile) Pityriasis rubra pilaris. Int J Dermatol 2006; 45:438.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/38\" class=\"nounderline abstract_t\">Garretson CB, Machan ML, Krejci-Manwaring J, et al. Letter: Adenocarcinoma of the lung associated with pityriasis rubra pilaris. Dermatol Online J 2011; 17:14.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/39\" class=\"nounderline abstract_t\">Kurzydlo AM, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol 2004; 45:130.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/40\" class=\"nounderline abstract_t\">Batinac T, Kujundzi&#263; M, Peternel S, et al. Pityriasis rubra pilaris in association with laryngeal carcinoma. Clin Exp Dermatol 2009; 34:e917.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/41\" class=\"nounderline abstract_t\">S&aacute;nchez-Rega&ntilde;a M, L&oacute;pez-Gil F, Salleras M, Umbert P. Pityriasis rubra pilaris as the initial manifestation of internal neoplasia. Clin Exp Dermatol 1995; 20:436.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/42\" class=\"nounderline abstract_t\">Batchelor RJ, Yung A, Merchant W, Goodfield MJ. Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma? Clin Exp Dermatol 2005; 30:442.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/43\" class=\"nounderline abstract_t\">Sharma S, Weiss GR, Paulger B. Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma. Dermatology 1997; 194:166.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/44\" class=\"nounderline abstract_t\">Reinhardt LA, Rosen T. Pityriasis rubra pilaris as the initial manifestation of leukemia. Cutis 1983; 31:100.</a></li><li class=\"breakAll\">Weedon D. The psoriasiform reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Weedon D, Strutton G, Rubin AI (Eds), Elsevier Limited, Edinburgh 2010. p.71.</li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/46\" class=\"nounderline abstract_t\">Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 1994; 31:997.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/47\" class=\"nounderline abstract_t\">Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol 1982; 6:710.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/48\" class=\"nounderline abstract_t\">Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol 1990; 22:792.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/49\" class=\"nounderline abstract_t\">Clayton BD, Jorizzo JL, Hitchcock MG, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol 1997; 36:959.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/50\" class=\"nounderline abstract_t\">Cohen PR, Prystowsky JH. Pityriasis rubra pilaris: a review of diagnosis and treatment. J Am Acad Dermatol 1989; 20:801.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/51\" class=\"nounderline abstract_t\">Chapalain V, Beylot-Barry M, Doutre MS, et al. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatolog Treat 1999; 10:113.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/52\" class=\"nounderline abstract_t\">Ross NA, Chung HJ, Li Q, et al. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients. JAMA Dermatol 2016; 152:670.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/53\" class=\"nounderline abstract_t\">Selvaag E, Haedersdal M, Thomsen K. Pityriasis rubra pilaris: a retrospective study of 12 patients. J Eur Acad Dermatol Venereol 2000; 14:514.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/54\" class=\"nounderline abstract_t\">Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol 1994; 130:675.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/55\" class=\"nounderline abstract_t\">Caldarola G, Zampetti A, De Simone C, et al. Circumscribed pityriasis rubra pilaris type IV. Clin Exp Dermatol 2007; 32:471.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/56\" class=\"nounderline abstract_t\">Karimian-Teherani D, Parissa M, Tanew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol 2008; 25:125.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/57\" class=\"nounderline abstract_t\">Molin S, Ruzicka T. Treatment of refractory pityriasis rubra pilaris with oral alitretinoin: case report. Br J Dermatol 2010; 163:221.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/58\" class=\"nounderline abstract_t\">Schmitt L, Inhoff O, Dippel E. Oral alitretinoin for the treatment of recalcitrant pityriasis rubra pilaris. Case Rep Dermatol 2011; 3:85.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/59\" class=\"nounderline abstract_t\">Amann PM, Susic M, Gl&uuml;der F, et al. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol 2015; 95:329.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/60\" class=\"nounderline abstract_t\">Pamp&iacute;n A, G&oacute;mez-de la Fuente E, Caro Guti&eacute;rrez MD, L&oacute;pez-Estebaranz JL. Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin. J Am Acad Dermatol 2013; 69:e105.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/61\" class=\"nounderline abstract_t\">van Dooren-Greebe RJ, van de Kerkhof PC. Extensive extraspinal hyperostoses after long-term oral retinoid treatment in a patient with pityriasis rubra pilaris. J Am Acad Dermatol 1995; 32:322.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/62\" class=\"nounderline abstract_t\">DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176.</a></li><li class=\"breakAll\">Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, Philadelphia 2007. p.275.</li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/64\" class=\"nounderline abstract_t\">Ormerod AD, Campalani E, Goodfield MJ, BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162:952.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/65\" class=\"nounderline abstract_t\">Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49:S1.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/66\" class=\"nounderline abstract_t\">Durairaj VD, Horsley MB. Resolution of pityriasis rubra pilaris-induced cicatricial ectropion with systemic low-dose methotrexate. Am J Ophthalmol 2007; 143:709.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/67\" class=\"nounderline abstract_t\">Garcovich S, Di Giampetruzzi AR, Antonelli G, et al. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol 2010; 24:881.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/68\" class=\"nounderline abstract_t\">Davis KF, Wu JJ, Murase JE, et al. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007; 143:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/69\" class=\"nounderline abstract_t\">Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol 2008; 158:642.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/70\" class=\"nounderline abstract_t\">Cox V, Lesesky EB, Garcia BD, O'Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol 2008; 59:S113.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/71\" class=\"nounderline abstract_t\">Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol 1999; 38:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/72\" class=\"nounderline abstract_t\">Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol 1986; 3:446.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/73\" class=\"nounderline abstract_t\">Meier S. Development of the chick embryo mesoblast: pronephros, lateral plate, and early vasculature. J Embryol Exp Morphol 1980; 55:291.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/74\" class=\"nounderline abstract_t\">Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol 2006; 47:124.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/75\" class=\"nounderline abstract_t\">Ruiz-Genao DP, Lopez-Estebaranz JL, Naz-Villalba E, et al. Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol 2007; 87:552.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/76\" class=\"nounderline abstract_t\">Petrof G, Almaani N, Archer CB, et al. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol 2013; 27:e131.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/77\" class=\"nounderline abstract_t\">Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol 2009; 145:99.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/78\" class=\"nounderline abstract_t\">Schreml S, Zeller V, Babilas P, et al. Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol 2010; 35:792.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/79\" class=\"nounderline abstract_t\">O'Kane D, Devereux CE, Walsh MY, Hoey SE. Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol 2010; 35:e155.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/80\" class=\"nounderline abstract_t\">Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 2010; 163:655.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/81\" class=\"nounderline abstract_t\">Ruiz Villaverde R, S&aacute;nchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol 2010; 20:630.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/82\" class=\"nounderline abstract_t\">Eytan O, Sarig O, Sprecher E, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol 2014; 171:420.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/83\" class=\"nounderline abstract_t\">Balestri R, Bardazzi F, Antonucci A. Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris? Br J Dermatol 2010; 163:896.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/84\" class=\"nounderline abstract_t\">Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol 2016; 152:1278.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/85\" class=\"nounderline abstract_t\">Yaniv R, Barzilai A, Trau H. Pityriasis rubra pilaris exacerbated by ultraviolet B phototherapy. Dermatology 1994; 189:313.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/86\" class=\"nounderline abstract_t\">Kaskel P, Grundmann-Kollmann M, Schiller PI, et al. Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol 1999; 140:769.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/87\" class=\"nounderline abstract_t\">Marguery MC, Durand-Malgouyres C, Bayle-Lebey P, et al. Photosensitive and phototriggered pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed 1994; 10:42.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/88\" class=\"nounderline abstract_t\">Mainardi L, Caccialanza M, Piccinno R. [Efficacy of photochemotherapy in a case of pityriasis rubra pilaris]. G Ital Dermatol Venereol 1990; 125:537.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/89\" class=\"nounderline abstract_t\">Lynch WS, Martin JS, Roenigk HH Jr. Clinical results of photochemotherapy. The Cleveland Clinic experience. Cutis 1977; 20:477.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/90\" class=\"nounderline abstract_t\">Vergilis-Kalner IJ, Mann DJ, Wasserman J, et al. Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy. J Drugs Dermatol 2009; 8:270.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/91\" class=\"nounderline abstract_t\">Betto P, Vassilopoulou A, Colombari R, Veller-Fornasa C. Acute juvenile pityriasis rubra pilaris: a case report after mononucleosis infection. G Ital Dermatol Venereol 2008; 143:271.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/92\" class=\"nounderline abstract_t\">Kirby B, Watson R. Pityriasis rubra pilaris treated with acitretin and narrow-band ultraviolet B (Re-TL-01). Br J Dermatol 2000; 142:376.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/93\" class=\"nounderline abstract_t\">Booth AV, Ma L. Pityriasis rubra pilaris, type 1. Dermatol Online J 2005; 11:9.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/94\" class=\"nounderline abstract_t\">Herbst RA, Vogelbruch M, Ehnis A, et al. Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol 2000; 142:574.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/95\" class=\"nounderline abstract_t\">Klein A, Szeimies RM, Landthaler M, Karrer S. Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology 2007; 215:72.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/96\" class=\"nounderline abstract_t\">Neess CM, Hinrichs R, Dissemond J, et al. Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving RE-PUVA therapy. Clin Exp Dermatol 2000; 25:209.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/97\" class=\"nounderline abstract_t\">Kaskel P, Peter RU, Kerscher M. Phototesting and phototherapy in pityriasis rubra pilaris. Br J Dermatol 2001; 144:430.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/98\" class=\"nounderline abstract_t\">Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol 2003; 149:202.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/99\" class=\"nounderline abstract_t\">Usuki K, Sekiyama M, Shimada T, et al. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology 2000; 200:324.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/100\" class=\"nounderline abstract_t\">Rosenbach A, Lowe NJ. Pityriasis rubra pilaris and cyclosporine. Arch Dermatol 1993; 129:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/101\" class=\"nounderline abstract_t\">Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol 1972; 87:42.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/102\" class=\"nounderline abstract_t\">Schram ME, Borgonjen RJ, Bik CM, et al. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011; 147:474.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/103\" class=\"nounderline abstract_t\">Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126:339.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/104\" class=\"nounderline abstract_t\">Coras B, Vogt TH, Ulrich H, et al. Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris? Br J Dermatol 2005; 152:388.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/105\" class=\"nounderline abstract_t\">Popova L, Darlenski R, Tsankov N. Penicillin and vitamin A as possible therapeutic agents in pityriasis rubra pilaris. J Dtsch Dermatol Ges 2010; 8:354.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/106\" class=\"nounderline abstract_t\">Ahn SY, Kim JH, Ahn SK, Oh YS. Clinical improvement of pityriasis rubra pilaris with antibiotic therapy. Eur J Dermatol 2011; 21:106.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/107\" class=\"nounderline abstract_t\">Hofer A, M&uuml;llegger R, Kerl H, Wolf P. Extracorporeal photochemotherapy for the treatment of erythrodermic pityriasis rubra pilaris. Arch Dermatol 1999; 135:475.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/108\" class=\"nounderline abstract_t\">Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol 2007; 156:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/pityriasis-rubra-pilaris/abstract/109\" class=\"nounderline abstract_t\">Krase IZ, Cavanaugh K, Curiel-Lewandrowski C. Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast. JAMA Dermatol 2016; 152:348.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15283 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1140890684\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H6824927\" id=\"outline-link-H6824927\">INTRODUCTION</a></li><li><a href=\"#H187071461\" id=\"outline-link-H187071461\">HISTORY</a></li><li><a href=\"#H6824934\" id=\"outline-link-H6824934\">EPIDEMIOLOGY</a></li><li><a href=\"#H6824941\" id=\"outline-link-H6824941\">PATHOGENESIS</a></li><li><a href=\"#H6824948\" id=\"outline-link-H6824948\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H427351550\" id=\"outline-link-H427351550\">Type I (classic adult)</a></li><li><a href=\"#H427351778\" id=\"outline-link-H427351778\">Type II (atypical adult)</a></li><li><a href=\"#H427351705\" id=\"outline-link-H427351705\">Type III (classic juvenile)</a></li><li><a href=\"#H427351790\" id=\"outline-link-H427351790\">Type IV (circumscribed juvenile)</a></li><li><a href=\"#H427351843\" id=\"outline-link-H427351843\">Type V (atypical juvenile)</a></li><li><a href=\"#H427351863\" id=\"outline-link-H427351863\">Type VI (HIV-associated)</a></li><li><a href=\"#H567847\" id=\"outline-link-H567847\">Mucosal involvement</a></li></ul></li><li><a href=\"#H61283694\" id=\"outline-link-H61283694\">ASSOCIATED DISORDERS</a></li><li><a href=\"#H6824990\" id=\"outline-link-H6824990\">DIAGNOSIS</a><ul><li><a href=\"#H427352175\" id=\"outline-link-H427352175\">Histopathology</a></li></ul></li><li><a href=\"#H427352191\" id=\"outline-link-H427352191\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H6824997\" id=\"outline-link-H6824997\">TREATMENT</a><ul><li><a href=\"#H427352246\" id=\"outline-link-H427352246\">Approach to therapy</a></li><li><a href=\"#H562911\" id=\"outline-link-H562911\">Topical therapy</a></li><li><a href=\"#H427352231\" id=\"outline-link-H427352231\">Systemic therapy</a><ul><li><a href=\"#H427352357\" id=\"outline-link-H427352357\">- First-line systemic therapy</a><ul><li><a href=\"#H427352254\" id=\"outline-link-H427352254\">Systemic retinoids</a></li></ul></li><li><a href=\"#H427352372\" id=\"outline-link-H427352372\">- Second-line systemic therapy</a><ul><li><a href=\"#H427352268\" id=\"outline-link-H427352268\">Methotrexate</a></li></ul></li><li><a href=\"#H427352387\" id=\"outline-link-H427352387\">- Additional therapies</a><ul><li><a href=\"#H427352330\" id=\"outline-link-H427352330\">Biologic agents</a></li><li><a href=\"#H563751\" id=\"outline-link-H563751\">Phototherapy</a></li><li><a href=\"#H1140890749\" id=\"outline-link-H1140890749\">Immunosuppressants</a></li><li><a href=\"#H427352338\" id=\"outline-link-H427352338\">Other</a></li></ul></li></ul></li></ul></li><li><a href=\"#H6825039\" id=\"outline-link-H6825039\">PROGNOSIS</a></li><li><a href=\"#H1140890684\" id=\"outline-link-H1140890684\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15283|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/86471\" class=\"graphic graphic_picture\">- Pityriasis rubra pilaris with islands of sparing</a></li><li><a href=\"image.htm?imageKey=DERM/86473\" class=\"graphic graphic_picture\">- Pityriasis rubra pilaris islands of sparing close view</a></li><li><a href=\"image.htm?imageKey=DERM/86472\" class=\"graphic graphic_picture\">- Pityriasis rubra pilaris follicular papules</a></li><li><a href=\"image.htm?imageKey=DERM/86475\" class=\"graphic graphic_picture\">- Pityriasis rubra pilaris follicular papules in dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/86474\" class=\"graphic graphic_picture\">- Pityriasis rubra pilaris plantar hyperkeratosis</a></li><li><a href=\"image.htm?imageKey=DERM/86476\" class=\"graphic graphic_picture\">- Pityriasis rubra pilaris face and scalp involvement</a></li><li><a href=\"image.htm?imageKey=DERM/87152\" class=\"graphic graphic_picture\">- Classic juvenile pityriasis rubra pilaris</a></li><li><a href=\"image.htm?imageKey=DERM/87153\" class=\"graphic graphic_picture\">- Classic juvenile pityriasis rubra pilaris - Legs</a></li><li><a href=\"image.htm?imageKey=DERM/87154\" class=\"graphic graphic_picture\">- Classic juvenile pityriasis rubra pilaris - Back</a></li><li><a href=\"image.htm?imageKey=DERM/70962\" class=\"graphic graphic_picture\">- Nail psoriasis pits</a></li><li><a href=\"image.htm?imageKey=DERM/66374\" class=\"graphic graphic_picture\">- Nail psoriasis oil drop</a></li><li><a href=\"image.htm?imageKey=DERM/87590\" class=\"graphic graphic_picture\">- Lichen spinulosus</a></li><li><a href=\"image.htm?imageKey=DERM/68488\" class=\"graphic graphic_picture\">- Keratosis pilaris dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/60786\" class=\"graphic graphic_picture\">- Keratosis pilaris light skin</a></li></ul></li><li><div id=\"DERM/15283|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/87505\" class=\"graphic graphic_table\">- Classification of pityriasis rubra pilaris</a></li><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of psoriasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use\" class=\"medical medical_review\">General principles of dermatologic therapy and topical corticosteroid use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate\" class=\"medical medical_review\">Major side effects of low-dose methotrexate</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris\" class=\"medical medical_review\">Oral isotretinoin therapy for acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-vitamin-a\" class=\"medical medical_review\">Overview of vitamin A</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-and-side-effects-of-azathioprine-when-used-in-rheumatic-diseases\" class=\"medical medical_review\">Pharmacology and side effects of azathioprine when used in rheumatic diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-cyclosporine-and-tacrolimus\" class=\"medical medical_review\">Pharmacology of cyclosporine and tacrolimus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=photosensitivity-disorders-photodermatoses-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-genodermatoses\" class=\"medical medical_review\">The genodermatoses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-psoriasis-in-adults\" class=\"medical medical_review\">Treatment of psoriasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects\" class=\"medical medical_review\">Tumor necrosis factor-alpha inhibitors: An overview of adverse effects</a></li></ul></div></div>","javascript":null}